Seres Therapeutics (MCRB) filed an 8-K on November 5, 2025, furnishing Q3 2025 financial results and operational updates.
Financially, the company reported net income from continuing operations of $8.2M for Q3 2025, largely attributed to a $27.2M installment received from the VOWST asset sale. R&D expenses decreased year-over-year. As of September 30, 2025, cash and equivalents stood at $47.6M. Following cost reductions, the company projects its cash runway will fund operations through Q2 2026.
Strategically, focus remains on advancing SER-155, which previously showed a 77% relative risk
...